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INTRODUCTION {#cncr31128-sec-0005}
============

Cachexia is commonly related to many clinically important conditions, such as anorexia, inflammation, and degradation of skeletal muscle protein, in which muscle wasting plays a key role. Cachexia is frequently observed in patients with cancer (50%‐80%) and leads to approximately 20% of deaths among cancer patients.[1](#cncr31128-bib-0001){ref-type="ref"}, [2](#cncr31128-bib-0002){ref-type="ref"}, [3](#cncr31128-bib-0003){ref-type="ref"}, [4](#cncr31128-bib-0004){ref-type="ref"}, [5](#cncr31128-bib-0005){ref-type="ref"} Moreover, cancer cachexia not only is associated with higher rates of toxicity from chemotherapeutic drugs[6](#cncr31128-bib-0006){ref-type="ref"} but also leads to a poor prognosis as well as reduced quality of life (QOL).[7](#cncr31128-bib-0007){ref-type="ref"}

Cancer cachexia cannot be completely reversed with conventional nutritional support,[8](#cncr31128-bib-0008){ref-type="ref"} and there are limited pharmacological therapies useful for the management of cachexia.

Ghrelin, a peptide hormone produced by ghrelin‐producing endocrine cells in the gut, acts as a regulator of hunger, which is also involved in the regulation of food intake.[9](#cncr31128-bib-0009){ref-type="ref"}, [10](#cncr31128-bib-0010){ref-type="ref"}, [11](#cncr31128-bib-0011){ref-type="ref"} Furthermore, ghrelin induces the secretion of growth hormone and thereby acts as a growth hormone secretagogue.[12](#cncr31128-bib-0012){ref-type="ref"}, [13](#cncr31128-bib-0013){ref-type="ref"}

Anamorelin (ONO‐7643) is an orally active, high‐affinity, selective agonist of the ghrelin receptor.[14](#cncr31128-bib-0014){ref-type="ref"}, [15](#cncr31128-bib-0015){ref-type="ref"} Previous phase 1 and 2 trials have demonstrated the safety and efficacy of anamorelin treatment for increasing body weight, lean body mass (LBM), and food intake.[16](#cncr31128-bib-0016){ref-type="ref"}, [17](#cncr31128-bib-0017){ref-type="ref"}, [18](#cncr31128-bib-0018){ref-type="ref"} Two multinational phase 3 clinical studies in patients with advanced non--small cell lung cancer (NSCLC) and cachexia reported that anamorelin administration for 12 weeks increased LBM and body weight and substantially improved the symptoms of anorexia/cachexia.[19](#cncr31128-bib-0019){ref-type="ref"}

A randomized, double‐blind, phase 2 trial investigated 50 and 100 mg of anamorelin versus a placebo in Japanese patients with NSCLC and cachexia; treatment with 100 mg of anamorelin in that study demonstrated improvements in LBM, body weight, appetite, and QOL with no tolerability issues.[20](#cncr31128-bib-0020){ref-type="ref"} Therefore, in the current study, 100 mg of anamorelin was selected to confirm its action in increasing LBM in Japanese patients with NSCLC and cachexia.

MATERIALS AND METHODS {#cncr31128-sec-0006}
=====================

Study Design {#cncr31128-sec-0007}
------------

We conducted a multicenter (43 sites in Japan), randomized, double‐blind, placebo‐controlled trial that comprised an observation/run‐in period of 2 weeks, a treatment period of 12 weeks, and a follow‐up period of 4 weeks. Visits during the treatment period were planned at weeks 0, (baseline/randomization), 1, 3, 6, 9, and 12. All procedures followed during this study were in accordance with the spirit of the Declaration of Helsinki, the study protocol, the standards specified under the Pharmaceutical Affairs Act of Japan (article 80, paragraph 2 and article 14, paragraph 3), and Good Clinical Practice (effective as of April 1, 1997; Japanese Ministry of Health and Welfare Ordinance No. 28). Ethics committee approval for the study was obtained from each center.

Patients {#cncr31128-sec-0008}
--------

This study included patients with stage III or IV NSCLC who were not to undergo an operation, were 20 years old or older, had involuntary weight loss ≥ 5% within the last 6 months, had anorexia, had 2 or more applicable symptoms (fatigue, malaise, reduced overall muscular strength, and arm muscle circumference \[in centimeters\] \< 10th percentile), and had more than 1 of the following conditions: albumin level \< 3.2 g/dL, C‐reactive protein level \> 5.0 mg/L, hemoglobin level \< 12 g/dL, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, and estimated life expectancy ≥ 4 months. Anorexia, malaise, fatigue, and reduced muscular strength needed to be grade 1 or higher according to the National Cancer Institute\'s Common Terminology Criteria for Adverse Events (version 4.0). The following formula was used to ascertain the arm muscle circumference:

Arm muscle circumference (cm) = Arm circumference (cm) − 3.14 × Triceps skinfold thickness (mm)/10.

Patients were excluded if they had known symptomatic brain metastases or uncontrolled diabetes. Written informed consent was obtained from each patient. All eligible patients were randomized by a centralized allocation center and were further stratified by the enrollment site and reductions in weight during the last 6 months (5%‐10% and \>10%). The randomization methodology used a randomization table and sealed envelopes to randomize the patients.

Interventions and Concomitant Therapies {#cncr31128-sec-0009}
---------------------------------------

After enrollment, patients were randomly assigned to either 100 mg of anamorelin or a placebo once daily throughout the therapy period. In this study, patients were enrolled regardless of their treatment history with chemotherapy for NSCLC, but they were prohibited from newly taking epidermal growth factor receptor tyrosine kinase inhibitors during the treatment period because of their possible effect on the QOL assessment.

During the study period, radiotherapy (other than palliative radiation therapy for bone metastases or radiation therapy for metastases in the brain), general corticosteroids, growth hormone formulations, medroxyprogesterone, megestrol acetate, Chinese herbal drugs, antiarrhythmic drugs, antitumor anthracyclines, inhibitors and inducers of cytochrome P450 3A4, and other experimental treatments were not permitted.

Efficacy Assessments {#cncr31128-sec-0010}
--------------------

The primary endpoint of the trial was the mean change in LBM (estimated by dual‐energy x‐ray absorptiometry \[DEXA\]) from the baseline over the 12‐week treatment period. The secondary endpoints of the study were changes in the body weight, body composition (ascertained by DEXA), appetite, Cancer Fatigue Scale (CFS) score, ECOG PS, Karnofsky Performance Scale (KPS) score, handgrip strength (HGS), Quality‐of‐Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL‐ACD) score, 6‐minute walk test (6MWT) results, and serum biomarkers. The LBM and other body composition--related variables, ECOG PS, KPS, HGS, 6MWT, and serum biomarkers were determined at the baseline and in weeks 3, 6, 9, and 12. The body weight, QOL‐ACD score, and CFS score were determined at the baseline and in weeks 1, 3, 6, 9, and 12. In addition, the efficacy parameters were recorded after treatment discontinuation.

Body composition was determined via DEXA with either the GE Lunar system (GE, Wauwatosa, Wisconsin) or the Hologic system (Hologic, Bedford, Massachusetts). DEXA was used to assess the LBM, fat mass, bone mineral content, and overall body mass by means of standardized methods. A grip dynamometer (Tracker Freedom Wireless Grip; JTECH Medical, Midvale, Utah) was used for the measurement of HGS.

The QOL‐ACD (see online supporting information) is a self‐rated measure assessing the condition of a patient during the last few days according to a 1 to 5 scale, and it is composed of 4 domains (functional, physical, mental, and psychosocial) and a global face scale developed as a generic questionnaire for assessing QOL in Japanese cancer patients receiving chemotherapy.[21](#cncr31128-bib-0021){ref-type="ref"} The CFS is a self‐rated scale evaluating current fatigue in cancer patients, and it has 3 dimensions (physical fatigue, affective fatigue, and cognitive fatigue). The scale is composed of 15 items scored on a 1 to 5 scale for a maximum score of 60, with higher scores indicating more severe fatigue. ECOG PS and KPS were used to quantify the PS of the patients. After a ≥ 12‐hour fast, blood samples were collected for the estimation of insulin‐like growth factor 1 (IGF‐1), insulin‐like growth factor‐binding protein 3 (IGFBP‐3), and prealbumin. Laboratory tests were performed at each study site.

Safety {#cncr31128-sec-0011}
------

The safety parameters included the vital signs, electrocardiography (centrally assessed) with all 12 leads, status of the tumor (evaluated by investigators using Response Evaluation Criteria in Solid Tumors \[RECIST\] guidelines), clinical laboratory tests, and adverse events (AEs). AEs were reported with the National Cancer Institute\'s Common Terminology Criteria for Adverse Events (version 4.0), and they were classified according to the system organ class/preferred term.

Statistical Analysis {#cncr31128-sec-0012}
--------------------

Analyses were performed according to the predetermined study protocol and statistical analysis plan. The full analysis set (FAS) was used for the analysis of all efficacy variables. The FAS comprised all eligible patients who had undergone a minimum of 1 efficacy assessment after the initiation of the study drug. The safety analysis set was used for the analysis of safety data and comprised all patients who had received the study drug at least once.

The findings of a phase 2 trial (ONO‐7643‐03), in which the mean difference in LBM (according to DEXA) between 100 mg of anamorelin and the placebo was 0.89 ± 1.94 kg, were used to determine the sample size for this study.[20](#cncr31128-bib-0020){ref-type="ref"} At least 76 patients were required in each treatment arm to reject the null hypothesis at *P* \< .05 and a power of 80%. Under the assumption that approximately 10% of the patients would withdraw/drop out of the study, a total of 170 patients (85 patients per group) were to be enrolled. Descriptive statistics were used to summarize the baseline parameters. An analysis of covariance for repeated measurement data, using the study arm, time point, and prior reductions in weight (5%‐10% and \>10%) as fixed factors and the baseline value as a covariate, was used to analyze efficacy parameters. The difference in the least squares mean from the initiation of treatment to a specific point of time was determined for both groups. The least squares mean differences between patients who received anamorelin and those who received the placebo were determined with 95% confidence intervals (CIs). A study arm--point of time interaction was incorporated for the assessment of secondary endpoints (differences in the body mass composition, QOL‐ACD score, CFS score, body weight, KPS, serum biomarkers, HGS, and 6MWT results). Descriptive statistics were used to assess safety parameters and are reported as numbers and percentages of patients. The total incidence of AEs and adverse drug reactions (ADRs) was compared between the study groups with the chi‐square test. There was no adjustment for the multiplicity of statistical testing, and an imputation method was not used for missing data.

RESULTS {#cncr31128-sec-0013}
=======

Patients {#cncr31128-sec-0014}
--------

A total of 174 patients were enrolled in this study from May 2014 to October 2015. Ninety of these 174 patients were randomized to the placebo group, and 84 were randomized to the 100‐mg anamorelin group (Fig. [1](#cncr31128-fig-0001){ref-type="fig"}). One patient did not receive treatment. One patient treated with 100 mg of anamorelin failed to meet the inclusion criteria and hence was excluded from the FAS. The FAS comprised 172 patients, with 90 and 82 in the placebo and anamorelin groups, respectively. There were 11 deaths in the placebo group and 5 deaths in the anamorelin group. AEs led to treatment discontinuation in 2 patients from the placebo group and in 5 patients from the anamorelin group. The baseline characteristics of the 2 groups were similar (Table [1](#cncr31128-tbl-0001){ref-type="table-wrap"}).

![Enrollment and outcomes.](CNCR-124-606-g001){#cncr31128-fig-0001}

###### 

Demographics and Baseline Characteristics of the Patients

  Parameter                                                      Placebo (n = 90)   Anamorelin (n = 84)
  -------------------------------------------------------------- ------------------ ---------------------
  Sex, No. (%)                                                                      
  Male                                                           57 (63.3)          59 (70.2)
  Female                                                         33 (36.7)          25 (29.8)
  Age, mean ± SD, y                                              67.2 ± 7.9         67.6 ± 9.9
  Weight, mean ± SD, kg                                          49.73 ± 8.32       52.23 ± 9.43
  BMI, mean ± SD, kg/m[2](#cncr31128-bib-0002){ref-type="ref"}   19.27 ± 2.31       19.81 ± 2.60
  Weight loss, No. (%)                                                              
  5‐10                                                           52 (57.8)          50 (60.2)
  \>10                                                           38 (42.2)          33 (39.8)
  Missing                                                        ―                  1
  Body composition (DEXA), mean ± SD, kg                                            
  LBM                                                            37.06 ± 6.34       38.88 ± 7.06
  Body fat                                                       10.68 ± 4.21       11.29 ± 5.04
  BMC                                                            1.90 ± 0.56        2.06 ± 0.57
  Total body mass                                                49.63 ± 8.61       52.23 ± 9.73
  Grip strength, mean ± SD, kg                                                      
  Dominant hand                                                  26.70 ± 8.01       27.87 ± 9.35
  Nondominant hand                                               25.12 ± 7.01       26.41 ± 8.30
  6‐min walk distance, mean ± SD, m                              375.7 ± 88.4       379.6 ± 89.6
  QOL‐ACD, mean ± SD                                             70.9 ± 13.0        74.9 ± 13.0
  Cancer Fatigue Scale, mean ± SD                                23.8 ± 9.7         24.4 ± 9.7
  ECOG PS, No. (%)                                                                  
  0                                                              13 (14.4)          9 (10.8)
  1                                                              65 (72.2)          64 (77.1)
  2                                                              12 (13.3)          10 (12.0)
  Missing                                                        ―                  1
  NSCLC type per histological criteria, No. (%)                                     
  Adenocarcinoma                                                 71 (78.9)          67 (79.8)
  Squamous cell                                                  16 (17.8)          14 (16.7)
  Other                                                          1 (1.1)            2 (2.4)
  Unknown                                                        2 (2.2)            1 (1.2)
  Disease stage                                                                     
  IIIA                                                           1 (1.1)            3 (3.6)
  IIIB                                                           11 (12.2)          6 (7.1)
  IV                                                             60 (66.7)          49 (58.3)
  Recurrence                                                     18 (20.0)          26 (31.0)
  Time from diagnosis to starting study drug, mean ± SD, d       609.4 ± 741.7      768.7 ± 698.0
  Previous history of chemotherapy (No. of times), No. (%)                          
  0                                                              2 (2.2)            2 (2.4)
  1                                                              31 (34.4)          20 (23.8)
  2                                                              18 (20.0)          19 (22.6)
  ≥3                                                             39 (43.3)          43 (51.2)
  Concomitant cancer therapy, No. (%)                                               
  Chemotherapy                                                   70 (77.8)          64 (76.2)
  EGFR TKI                                                       29 (32.2)          23 (27.7)
  Radiation                                                      6 (6.7)            7 (8.3)
  Supportive care                                                19 (21.1)          18 (21.7)
  Missing                                                        ―                  1

Abbreviations: BMC, bone mineral content; BMI, body mass index; DEXA, dual‐energy x‐ray absorptiometry; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LBM, lean body mass; NSCLC, non--small cell lung cancer; PS, performance status; QOL‐ACD, Quality‐of‐Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (Kurihara Group Questionnaire); SD, standard deviation; TKI, tyrosine kinase inhibitor.

LBM {#cncr31128-sec-0015}
---

As shown in Figure [2](#cncr31128-fig-0002){ref-type="fig"}, the increase in LBM over 12 weeks was found to be significantly larger in the anamorelin‐treated patients versus the placebo‐treated patients, with least squares means and standard errors of 1.38 ± 0.18 and −0.17 ± 0.17 kg, respectively. Overall, the change in the anamorelin‐treated patients versus the placebo‐treated patients was 1.56 kg (95% CI, 1.11‐2.00 kg; *P* \< .0001). At week 3 and thereafter, a significant difference (*P* \< .0001) in the LBM gain in comparison with the baseline was noted between the treatment groups.

![Time‐course changes for the anamorelin and placebo groups in (A) lean body mass and (B) body weight and (C) changes in primary and secondary efficacy measures from the baseline over 12 weeks. QOL‐ACD indicates Quality‐of‐Life Questionnaire for Cancer Patients Treated With Anticancer Drugs.](CNCR-124-606-g002){#cncr31128-fig-0002}

Body Weight {#cncr31128-sec-0016}
-----------

In comparison with the placebo, anamorelin induced a significant weight gain (Fig. [2](#cncr31128-fig-0002){ref-type="fig"}), which is in agreement with anamorelin\'s mechanism of action and the LBM gain. The body weight gain was evident at week 1 of treatment and continued thereafter.

Other Body Composition Parameters {#cncr31128-sec-0017}
---------------------------------

In comparison with the placebo, anamorelin significantly increased other body composition parameters, including the total body mass, fat mass, appendicular LBM (arms and legs), and trunk LBM (Supporting Table 1 \[see online supporting information\]).

QOL‐ACD {#cncr31128-sec-0018}
-------

Throughout the study period from week 1, the anamorelin‐treated patients showed significant improvements in comparison with the placebo‐treated patients in the QOL‐ACD scores for items 7 to 11 ("physical condition"), item 8 ("Did you have a good appetite?"), item 9 ("Did you enjoy your meals?"), and item 11 ("Did you lose any weight?"; Fig. [3](#cncr31128-fig-0003){ref-type="fig"}A‐D). The efficacy of anamorelin was not definite in other domains.

![Time‐course changes for the anamorelin and placebo groups in the QOL‐ACD scores for (A) items 7 to 11 ("physical condition"), (B) item 8 ("Did you have a good appetite?"), (C) item 9 ("Did you enjoy your meals?"), and (D) item 11 ("Did you lose any weight?"). QOL‐ACD indicates Quality‐of‐Life Questionnaire for Cancer Patients Treated With Anticancer Drugs.](CNCR-124-606-g003){#cncr31128-fig-0003}

Other Secondary Endpoints {#cncr31128-sec-0019}
-------------------------

The effects of 100 mg of anamorelin on CFS, HGS, and 6MWT are shown in Figure [2](#cncr31128-fig-0002){ref-type="fig"} and Supporting Table 2 (see online supporting information). There were marginal effects on CFS, HGS, and 6MWT. In comparison with the placebo group, the anamorelin group showed significant increases in the serum IGF‐1, IGFBP‐3, and prealbumin levels (Fig. [4](#cncr31128-fig-0004){ref-type="fig"}A‐C).

![Time‐course changes for the anamorelin and placebo groups in (A) insulin‐like growth factor 1, (B) insulin‐like growth factor‐binding protein 3, and (C) prealbumin.](CNCR-124-606-g004){#cncr31128-fig-0004}

Safety {#cncr31128-sec-0020}
------

On the basis of the RECIST criteria, a complete response and a partial response were observed in 1 (1.5%) and 3 patients (4.5%), respectively, in the anamorelin‐treated group and in 0 (0.0%) and 2 patients (2.7%), respectively, in the placebo group. Stable disease was observed in 21 (31.3%) and 22 patients (29.7%) in the anamorelin‐treated and placebo groups, respectively. Thirty‐eight of the anamorelin‐treated patients (56.4%) showed progressive disease, whereas 47 patients (63.5%) in the placebo group did. Non--complete response/non--progressive disease cases were observed for 4 (6.0%) and 3 patients (4.1%) in the anamorelin‐treated and placebo groups, respectively. The median survival times were found to be similar for the 2 groups (8.08 months \[95% CI, 5.98‐11.56 months\] for anamorelin and 8.21 months \[95% CI, 6.67‐12.39 months\] for the placebo; hazard ratio, 1.17 \[95% CI, 0.82‐1.67\]; *P* = .3762).

Table [2](#cncr31128-tbl-0002){ref-type="table-wrap"} summarizes the overall incidences of AEs and ADRs. The frequency of AEs was found to be similar in the anamorelin group and the placebo group. On the other hand, the anamorelin group reported a significantly higher number of ADRs in comparison with the placebo group; however, all the ADRs were grade 3 or lower. The most common ADRs were first‐degree atrioventricular block and rash, which were followed by increased γ‐glutamyltransferase and diabetes mellitus. All these events were grade 1 or 2 except for 1 case of rash.

###### 

Safety

                                          Placebo (n = 90)   Anamorelin (n = 83)
  --------------------------------------- ------------------ ---------------------
  AEs, No. (%)                            73 (81.1)          74 (89.2)
  AEs                                                        
  Difference vs placebo, % (95% CI)                          8.0 (--2.4, 18.5)
  *P*                                                        .1390
  SAEs, No. (%)                           8 (8.9)            16 (19.3)
  Discontinuations due to AEs, No. (%)    2 (2.2)            3 (3.6)
  ADRs, No. (%)                           20 (22.2)          34 (41.0)
  ADRs                                                       
  Difference vs placebo, % (95% CI)                          18.7 (5.1, 32.4)
  *P*                                                        .0079
  Serious ADRs, No. (%)                   0 (0.0)            2 (2.4)
  Discontinuations due to ADRs, No. (%)   1 (1.1)            2 (2.4)
  Deaths, No. (%)                         11 (12.2)          5 (6.0)
  ADRs by grade, No. (%)                                     
  1/2                                     18 (20.0)          28 (33.7)
  3                                       2 (2.2)            6 (7.2)
  ADRs in \> 2% of patients, No. (%)                         
  First‐degree atrioventricular block     0 (0.0)            5 (6.0)
  Tachycardia                             0 (0.0)            2 (2.4)
  Edema                                   0 (0.0)            2 (2.4)
  Peripheral edema                        0 (0.0)            2 (2.4)
  Pyrexia                                 0 (0.0)            2 (2.4)
  γ‐Glutamyltransferase increase          1 (1.1)            3 (3.6)
  Glycosylated hemoglobin increase        1 (1.1)            2 (2.4)
  Diabetes mellitus                       0 (0.0)            3 (3.6)
  Hyperglycemia                           1 (1.1)            2 (2.4)
  Headache                                1 (1.1)            2 (2.4)
  Rash                                    1 (1.1)            5 (6.0)
  Hypertension                            0 (0.0)            2 (2.4)
  Hot flush                               0 (0.0)            2 (2.4)

Abbreviations: ADR, adverse drug reaction; AE, adverse event; CI, confidence interval; SAE, severe adverse event.

DISCUSSION {#cncr31128-sec-0021}
==========

The current study demonstrated that anamorelin significantly improved LBM and body weight in Japanese patients with NSCLC and cachexia in comparison with a placebo. Significant improvements in LBM and body weight were observed in the anamorelin group at the early time points of week 3 and week 1, respectively, in comparison with the placebo group, and they were sustained thereafter during the 12‐week study period.

The National Comprehensive Cancer Network clinical guidelines for the management of anorexia/cachexia define the primary treatment goals as promoting weight gain/stabilization and relieving symptoms of anorexia.[22](#cncr31128-bib-0022){ref-type="ref"} Similarly, the clinical practice guidelines on cancer cachexia given by the European Palliative Care Research Collaborative specify that the treatment goals for cachexia should be a reversal of the loss of body weight and muscle mass and that the minimum objective must be the maintenance of body weight and the prevention of further body weight loss.[23](#cncr31128-bib-0023){ref-type="ref"} The results of the current study satisfy the treatment goals in these guidelines.

As for appetite, a considerable increase was reported in the anamorelin group versus the placebo group as early as week 1, and it was subsequently sustained throughout the study period. The increased level of prealbumin, a nutritional state marker, suggested increased food intake. Decreases in appetite and food intake are considered to be the main underlying causes for the worsening of the physical and psychological status in cancer patients.[24](#cncr31128-bib-0024){ref-type="ref"} Anorexia leads to QOL deterioration in cancer patients[25](#cncr31128-bib-0025){ref-type="ref"} and is also a prognostic factor.[26](#cncr31128-bib-0026){ref-type="ref"} Therefore, oncologists should consider ensuring sufficient energy and protein intake for all cancer patients.[27](#cncr31128-bib-0027){ref-type="ref"}

Under the present conditions, where there are no effective treatment methods for cancer cachexia, anamorelin may have great clinical significance by preventing weight loss and ameliorating anorexia.

In contrast, in the assessment of motor function, including HGS and 6MWT results, no improvement was observed after anamorelin administration. Previous researchers have suggested that patients who are affected by long‐term illness and systemic inflammation may display an unusual association between muscle mass and muscular strength.[28](#cncr31128-bib-0028){ref-type="ref"}, [29](#cncr31128-bib-0029){ref-type="ref"}, [30](#cncr31128-bib-0030){ref-type="ref"} Furthermore, the most suitable measure for muscle strength in advanced cancer patients is unidentified. The 6MWT measurements may have been affected by respiratory insufficiency in patients with NSCLC. The cause of cachexia is multifactorial, and pharmacological treatment alone may not be able to bring about a complete reversal of all features of the syndrome (especially improvements in motor function). Therefore, it is expected that a multimodal treatment combining medicine, exercise, and nutrition may improve the condition and symptoms of cachexia, including motor function.

In general, patients in the 2 treatment groups showed similar overall survival times and tumor responses as assessed by RECIST, and this indicated that the therapy had no effect on the progression of the disease. In addition, patient characteristics such as the disease stage and previous use of chemotherapy and prevailing factors that affect the prognosis were similar between the 2 treatment arms.

In comparison with patients receiving the placebo, the frequency of ADRs was significantly higher in patients receiving anamorelin; however, most deaths and treatment discontinuations were caused by disease progression and not by the study drugs. In comparison with the placebo‐treated patients, first‐degree atrioventricular block and rash occurred at rates ≥ 5%, and they had a higher incidence in the anamorelin‐treated patients. However, all first‐degree atrioventricular block cases were grade 1, and only 1 case of rash was grade 3; this suggests no major risk. The frequencies of these ADRs were observed to be higher in the current study versus the multinational phase 3 studies.[19](#cncr31128-bib-0019){ref-type="ref"} The frequent electrocardiogram measurements might have caused the higher incidence of first‐degree atrioventricular block. Although no apparent cause of rash has been identified, we think that there is a possibility that this might have been influenced by chemotherapy applied during the study. In agreement with previous studies,[19](#cncr31128-bib-0019){ref-type="ref"}, [20](#cncr31128-bib-0020){ref-type="ref"} increases in blood glucose levels were more frequently observed with anamorelin treatment; this was, however, controllable. The changes in glucose homeostasis might have been caused by effects of IGF‐1 and growth hormone on glucose metabolism or by a possible effect of the reversal of cancer anorexia/cachexia syndrome. These findings suggest that anamorelin is safe and well tolerated in Japanese cancer patients with cachexia.

The current research had some shortcomings. First, we could not confirm the efficacy of anamorelin by functional measures of HGS and 6MWT. Second, its efficacy for fatigue was not confirmed. The lack of a treatment effect observed for CFS may have arisen because fatigue associated with cancer is a problematic manifestation to ameliorate in patients with advanced cancer and particularly in patients with more symptomatic disease.[31](#cncr31128-bib-0031){ref-type="ref"}, [32](#cncr31128-bib-0032){ref-type="ref"} This is partly due to the multiple and complex causes of fatigue, including chemotherapy, anemia, nutritional issues, and pain.[33](#cncr31128-bib-0033){ref-type="ref"}

The efficacy of anamorelin in the current study for increasing LBM and body weight and improving anorexia symptoms and the nutritional state with no improvement in motor function is consistent with the recent results of 2 multinational phase 3 studies with anamorelin.[19](#cncr31128-bib-0019){ref-type="ref"} Although anamorelin cannot improve motor function or survival, it may be of great importance for alleviating anorexia, a highly unmet medical need, to help patients with advanced cancer to enjoy their meals and thereby achieve better QOL.

On the basis of our findings, once daily administration of 100 mg of anamorelin showed favorable results for LBM gains in Japanese patients with NSCLC and cachexia; hence 100 mg could be the desired dose for such patients. Anamorelin therapy was associated with augmentation of IGF‐1 and IGFBP‐3 levels, and this suggests an increase in the synthesis of proteins that can have direct growth effects on skeletal muscle. Moreover, anamorelin was associated with favorable improvements in appetite and increases in prealbumin, and this indicates an improved nutritional status. Even though the incidences of ADRs and treatment discontinuations due to AEs were higher in the anamorelin group, most of the treatment discontinuations were associated with the progression of disease and not with anamorelin. The efficacy of anamorelin to improve LBM and anorexia was thus confirmed in Japanese patients with NSCLC and cachexia. Because no effective treatment for cancer cachexia is currently available, anamorelin can be one of the beneficial treatment options.
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